AstraZeneca (LON:AZN) Earns “Overweight” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their overweight rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Monday, Borsen Zeitung reports. JPMorgan Chase & Co. currently has a GBX 7,900 ($103.23) target price on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the company. Citigroup reiterated a buy rating and issued a £100 ($130.67) target price (up from GBX 7,000 ($91.47)) on shares of AstraZeneca in a report on Wednesday, September 11th. Deutsche Bank lifted their target price on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the company a buy rating in a report on Monday, September 9th. Goldman Sachs Group set a GBX 5,500 ($71.87) target price on AstraZeneca and gave the company a sell rating in a report on Monday, September 2nd. Jefferies Financial Group reiterated a neutral rating on shares of AstraZeneca in a report on Thursday, August 29th. Finally, Shore Capital reiterated a buy rating on shares of AstraZeneca in a report on Tuesday, August 27th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company. AstraZeneca currently has a consensus rating of Hold and a consensus price target of GBX 7,050 ($92.12).

LON:AZN opened at GBX 6,947 ($90.77) on Monday. The firm has a market cap of $91.14 billion and a PE ratio of 40.58. The stock has a fifty day moving average price of GBX 7,180.61 and a 200 day moving average price of GBX 6,406.21. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,583 ($99.09). The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48.

The firm also recently declared a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were paid a GBX 71.90 ($0.94) dividend. This represents a yield of 1.07%. The ex-dividend date was Thursday, August 8th. AstraZeneca’s dividend payout ratio is presently 1.28%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.